TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03815890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses 240 mg flat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses 240 mg flat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses 240 mg flat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses 240 mg flat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses 240 mg flat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: single dose ipilimumab (1mg/kg) at day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: single dose ipilimumab (1mg/kg) at day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: two courses ipilimumab (1mg/kg) at day 1 and 21
Study: NCT02757105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEKINDA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03205774

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: 6 hours fasting and free oral intake of water
Description: Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: 6 hours fasting and free oral intake of water
Description: Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: 6 hours fasting and free oral intake of water
Description: Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
Study: NCT04057820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eat, Sleep, Console (ESC) care tool
Description: The ESC care approach emphasizes parental involvement, simplifies the assessment of infants with NOWS and focuses interventions on non-pharmacologic therapies.
Study: NCT04235868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell-derived derived pleiotropic factor
Description: After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fibroblast growth factor
Description: After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days.
Study: NCT03205774

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: 6 hours fasting and free oral intake of water
Description: Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
Study: NCT02057042

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
Study: NCT00137839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT04581460

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
Study: NCT02201108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Pharmaceutical form:film-coated tablet, Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:tablet, Route of administration: oral
Study: NCT00235170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent
Description: Cypher Sirolimus-eluting Coronary stent
Study: NCT04507880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Total Shoulder Arthroplasty
Description: The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: The shoulder hemiarthroplasty
Study: NCT02871882

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Emptying test
Description: participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Gastric Emptying test
Description: participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Oral Glucose Tolerance test
Description: Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Oral Glucose Tolerance test
Description: Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated bile acids sodium
Description: 500 mg tablets taken orally twice daily for 28 (+/- 4) days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally twice daily for 28 (+/- 4) days
Study: NCT02694432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GOALS
Description: 16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GOALS
Description: 16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minding GOALS
Description: 16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
Study: NCT00208546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21Capecitabine + bevacizumab + oxaliplatin
Description: 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab
Description: 3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
Study: NCT01405066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radiation Dose Audit Reports
Description: Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
Study: NCT03923296

Intervention type: DEVICE
Intervention: Blood measurement and monitoring
Description: Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Focus group interviews

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Focus group interviews
Study: NCT04461925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells
Description: i/v infusions
Study: NCT01405066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Seminar: Radiation Dose Reduction
Description: Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
Study: NCT02996643

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Assisted Group
Description: A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
Study: NCT00266851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 600 mg x 3 days, then 600 mg weekly x 11 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: 600 mg x 3 days, then 600 mg weekly x 11 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00853268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled-Release Oxycodone Hydrochloride 40 mg
Description: Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyContin® 40 mg tablet
Description: OxyContin® 40 mg tablet, single dose with food
Study: NCT06177574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/FTC/TAF
Description: TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
Study: NCT01486043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
Study: NCT01288976

Intervention type: DEVICE
Intervention: MitraClip
Description: The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets

Intervention type: DRUG
Intervention: Medical Management
Description: The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included

Intervention type: PROCEDURE
Intervention: Mitral Valve Surgery
Description: The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
Study: NCT01122394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TI
Description: Tailored intervention based on the transtheoretical model

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AP
Description: Attention placebo
Study: NCT00817687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: As prescribed; + early biopsy

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: mycophenolate mofetil [CellCept]
Description: As prescribed; + standard treatment
Study: NCT00039871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REBETOL (ribavirin; SCH 18908)
Description: REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
Study: NCT03049293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The impact of Midazolam levels in follicular fluid.
Study: NCT04512339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab injections (blinded labels)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
Study: NCT03031847

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Resynchronization Therapy Pacemaker
Description: Patients randomized to the pacemaker arm will receive a CRT-P device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Resynchronization Therapy Pacemaker
Description: Patients randomized to the pacemaker arm will receive a CRT-P device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Resynchronization Therapy Defibrillator
Description: Patients randomized to the defibrillator arm will receive a CRT-D device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Resynchronization Therapy Defibrillator
Description: Patients randomized to the defibrillator arm will receive a CRT-D device.
Study: NCT03598101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TONEFITreha
Description: The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
Study: NCT04461925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormones
Description: a moderate amount of dexamethasone i/v

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormones
Description: a moderate amount of dexamethasone i/v

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant Therapy
Description: Sub-Q

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant Therapy
Description: Sub-Q
Study: NCT04438655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antibiotic drugs
Description: Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Parenteral prophylaxis
Description: Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral prophylaxis
Description: Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg.
Study: NCT02140125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: subcutaneous administration
Study: NCT05050071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction
Description: Change in the bacterial load in response to different treatment procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction
Description: Change in the bacterial load in response to different treatment procedures
Study: NCT00633594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest
Study: NCT02140125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: subcutaneous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous administration
Study: NCT00061321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine and mulitvitamins
Description: Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine and mulitvitamins
Description: Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
Study: NCT03121443

Intervention type: OTHER
Intervention: Perfusion index
Description: supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
Study: NCT01583127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Behavioral Interventions & Supports
Description: Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
Study: NCT01527006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
Study: NCT00836667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® 100 mg Tablets
Description: 1 x 100 mg, single-dose fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 100 mg Tablets
Description: 1 x 100 mg, single-dose fed
Study: NCT04551976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Pay attention to the present moment, on purpose, in a nonjudgemental way.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Pay attention to the present moment, on purpose, in a nonjudgemental way.
Study: NCT01854463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2000IU per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: elemental calcium 200mg per day per 24 weeks
Study: NCT04596007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC83518 tablets
Description: Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04461925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Оxygen therapy
Description: Оxygen therapy, mechanical ventilation and other supportive therapies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Оxygen therapy
Description: Оxygen therapy, mechanical ventilation and other supportive therapies
Study: NCT00752973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MALG (malathion) Treatment
Description: MALG applied for 30 minutes
Study: NCT02392533

Intervention type: OTHER
Intervention: Education
Description: Education
Study: NCT03774095

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed pine nut oil
Description: Given 30 min prior to oral glucose tolerance test
Study: NCT03911258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swab versus nasal wash
Description: The type of procedure will be determine according to patient collaboration
Study: NCT03483194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy